DCF Advisers LLC Raises Stock Holdings in Evotec AG (NASDAQ:EVO)

Key Points

• DCF Advisers LLC increased its holdings in Evotec AG by 227.0% in the first quarter, acquiring an additional 521,708 shares to reach a total of 751,579 shares.
• Recent Hedge fund movements include Bank of America raising its position in Evotec by 262.5%, reflecting growing institutional interest in the stock.
• Wall Street analysts maintain a positive outlook with Royal Bank Of Canada reiterating an "outperform" rating and Deutsche Bank upgrading its rating from "sell" to "hold".

DCF Advisers LLC increased its position in Evotec AG (NASDAQ:EVO - Free Report) by 227.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 751,579 shares of the company's stock after purchasing an additional 521,708 shares during the quarter. Evotec makes up 1.2% of DCF Advisers LLC's portfolio, making the stock its 28th largest holding. DCF Advisers LLC owned approximately 0.21% of Evotec worth $2,510,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in shares of Evotec in the fourth quarter valued at about $27,000. Bank of America Corp DE boosted its stake in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares during the last quarter. Lighthouse Investment Partners LLC bought a new position in Evotec during the 4th quarter worth approximately $166,000. Finally, CSS LLC IL acquired a new stake in Evotec during the 4th quarter worth approximately $50,000. 5.81% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on EVO. Royal Bank Of Canada restated an "outperform" rating on shares of Evotec in a report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th.

Evotec Trading Down 0.7%

Shares of EVO stock traded down $0.03 during trading hours on Tuesday, hitting $3.85. 6,832 shares of the company were exchanged, compared to its average volume of 99,713. Evotec AG has a fifty-two week low of $2.84 and a fifty-two week high of $5.64. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.93 and a current ratio of 2.03. The company has a 50 day simple moving average of $4.10 and a two-hundred day simple moving average of $4.00.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.